Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study.
COVID-19
SARS-CoV-2
cancer
mortality
systemic anti-cancer treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
15
02
2021
revised:
12
03
2021
accepted:
14
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231
Identifiants
pubmed: 33809465
pii: cancers13061324
doi: 10.3390/cancers13061324
pmc: PMC7998451
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
JAMA Oncol. 2021 Feb 1;7(2):304-306
pubmed: 33331862
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Crit Care. 2020 May 15;24(1):228
pubmed: 32414403
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650523
Front Cardiovasc Med. 2020 Oct 09;7:585866
pubmed: 33195473
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Ther Adv Med Oncol. 2020 Oct 23;12:1758835920971147
pubmed: 33178336
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Intensive Care Med. 2017 Sep;43(9):1366-1382
pubmed: 28725926
Ann Oncol. 2021 Feb 12;:
pubmed: 33582237
JCO Glob Oncol. 2020 Sep;6:1461-1471
pubmed: 32997537
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Crit Rev Oncol Hematol. 2021 Feb 26;:103271
pubmed: 33647445
Cancer Treat Rev. 2020 Aug;88:102041
pubmed: 32516704